PredictImmune
PredictImmune is a Cambridge, UK-based private biotech developing prognostic tools that help physicians predict long-term clinical outcomes in patients with immune-mediated diseases, with a focus on inflammatory bowel disease. The company is anchored in Cambridge-linked research and funded by UK institutional and disease-foundation backers.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What PredictImmune does
PredictImmune is a Cambridge, UK-based private biotechnology company founded in 2017 that develops prognostic tools to support physicians treating patients with immune-mediated disease by predicting long-term clinical outcomes. The company's offering targets clinical decision-making in conditions such as inflammatory bowel disease — a focus reinforced by its 2023 partnership with the Crohn's & Colitis Foundation. Its core product is positioned as a prognostic test or platform, anchored in biomarker science originating from University of Cambridge research and developed via a leadership team combining scientific (CSO Eoin McKinney), clinical (CMO Kenneth Smith), and platform-delivery (VP Paul Lyons) expertise.
The company's revenue mechanics, pricing model, and go-to-market strategy are not disclosed in the available sources. Capital has been raised across six funding events cumulatively totaling approximately $31.4M (2017–2023), sourced from UK-aligned institutional and disease-foundation backers — Parkwalk Advisors, University of Cambridge Enterprise, Wren Capital, Wellcome Trust, Innovate UK, Business Growth Fund, Cambridge Innovation Capital, and the Crohn's & Colitis Foundation — implying reliance on non-dilutive and venture funding rather than commercial product revenue. Headcount sits at 11–50 employees, consistent with a translational-stage organization; no product pricing, customer logos, or commercial distribution channels were disclosed.
The firm's strategic posture is best characterized as clinical validation and platform maturation: founder-scientists run the R&D agenda, an independent chairman and CFO signal governance readiness, and disease-foundation partnerships point toward regulated diagnostic pathways (likely UKCA/CE-marked in vitro diagnostics) rather than direct-to-consumer or SaaS distribution. Absent disclosed revenue, the business model is best read as pre-commercial, with monetization to follow regulatory clearance, reimbursement, and clinical adoption milestones.
PredictImmune firmographics
Firmographics- Name
- PredictImmune
- Website
- https://predictimmune.com
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 11–50 employees
- Short description
- PredictImmune is a Cambridge, UK-based private biotech developing prognostic tools that help physicians predict long-term clinical outcomes in patients with immune-mediated diseases, with a focus on inflammatory bowel disease. The company is anchored in Cambridge-linked research and funded by UK institutional and disease-foundation backers.
- Ownership category
- akta.pro rank
PredictImmune industry classification
Industry- Product category
- Clinical Prognostics Software
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Predictive Biomarkers for Therapy Selection (response/non-response stratification) (HLAAAMAE)
- akta.pro secondary industries
- Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE), Diagnostic & Triage Decision Support (HLACAGAA)
Keywords
Where PredictImmune is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
PredictImmune business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations
PredictImmune product offering
Product offeringCore offering
PredictImmune develops and provides tools to physicians for use in the treatment of patients with immune-mediated disease, focused on predicting long-term clinical prognosis. The company applies proprietary biomarker science and predictive analytics to translate complex immunological data into clinically actionable long-term outcome forecasts that support personalized treatment planning.
Differentiator
Problem solved
Functional benefit
Products and services
- PredictImmune Prognostic Platform Physician-facing prognostic platform that predicts long-term clinical outcomes for patients with immune-mediated disease (notably inflammatory bowel disease), supporting personalized treatment planning and risk stratification.
Companies that use PredictImmune
Customer profileIdeal customer profiles1 record
PredictImmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
PredictImmune partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
PredictImmune competitors and assessment
Company assessmentDirect peers
- Prometheus Laboratories: Prometheus (a Nestlé Health Science company) develops and markets IBD diagnostic and prognostic testing (e.g., IBD Serology 7, PROMETHEUS® Crohn's Prognostic) — directly comparable to PredictImmune as both serve gastroenterologists with biomarker-based prognosis to inform treatment decisions in Crohn's disease and ulcerative colitis.
- Exagen Inc. Exagen markets proprietary blood-based diagnostic and prognostic tests for autoimmune diseases (e.g., AVISE CTD, AVISE Lupus Prognostic) and sells its assays through a CLIA lab to rheumatologists — directly analogous to PredictImmune's physician-facing prognostic-testing model in immune-mediated disease.
Broad incumbents
- Myriad Genetics: Myriad is an established molecular diagnostics company offering prognostic and predictive tests (e.g., Vectra DA for RA disease activity, risk-assessment panels) that target specialists managing autoimmune/immune-mediated disease — comparable as a broad incumbent providing physician-facing prognostic biomarker testing.
- Eurofins Scientific: Eurofins operates a global specialty diagnostics and clinical-testing platform, including autoimmune and IBD biomarker services to clinicians; relevant as a broad incumbent that could partner with, acquire, or compete against PredictImmune's prognostic testing platform.
Emerging players
- Adaptive Biotechnologies: Adaptive applies immune-receptor sequencing and immune-profiling to characterize immune-mediated disease states and predict clinical outcomes, analogous to PredictImmune's biomarker-based prognosis in immune-mediated conditions — a partial-overlap emerging player with an adjacent technology platform.
- CareDx: CareDx is a specialty diagnostics company whose AlloSure/AlloMap franchise monetizes prognostic biomarker testing paid for by transplant centers and payers — relevant as a comparable commercial model where a single-disease prognostic biomarker test is sold into a specialist physician channel.
- Vedanta Biosciences: Vedanta develops microbiome-based therapies for immune-mediated disease (including IBD) and operates in the same clinical/scientific Cambridge-cluster ecosystem; comparable as an immune-mediated-disease platform company pursuing biomarker-driven patient stratification in overlapping indications.
- Progentec Diagnostics: Progentec develops biomarker-driven diagnostics for autoimmune diseases (e.g., lupus, RA) intended to predict flares and disease progression — a direct functional competitor in the physician-facing prognostic-test niche that PredictImmune targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
PredictImmune social profiles
Digital presencePredictImmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
PredictImmune leadership team
Management profileNumber of profiles
Profiles6 records
PredictImmune funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PredictImmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PredictImmune
What does PredictImmune do?
PredictImmune develops and provides tools to physicians for use in the treatment of patients with immune-mediated disease, focused on predicting long-term clinical prognosis. The company applies proprietary biomarker science and predictive analytics to translate complex immunological data into clinically actionable long-term outcome forecasts that support personalized treatment planning.
When was PredictImmune founded?
PredictImmune was founded in 2017. It employs 11 to 50 people.
Where is PredictImmune based?
PredictImmune is headquartered in Cambridge, United Kingdom, in the Europe region.
Who are PredictImmune's main competitors?
Direct peers on record are Prometheus Laboratories and Exagen Inc.. Broad incumbents are Myriad Genetics and Eurofins Scientific. Emerging players are Adaptive Biotechnologies, CareDx, Vedanta Biosciences and Progentec Diagnostics.
Does PredictImmune have an API?
No public API is recorded for PredictImmune.
What industry is PredictImmune in?
PredictImmune's product category is Clinical Prognostics Software. Its primary akta.pro industry code is HLAAAMAE, Predictive Biomarkers for Therapy Selection (response/non-response stratification), with a secondary code of HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics. Its NAICS code is 325413 and its SIC code is 2835.